Cross-sectional study to assess the effectiveness of the patients’ alert card to inform on the risk of differentiation syndrome in AML patients treated with TIBSOVO® (Ivosidenib) (IMPACTA) First published 06/06/2024 Last updated 18/03/2026 EU PAS number:EUPAS1000000190 Study Ongoing